It's not hard to envision such a fictional scenario:
"We opted to purchase Company I to acquire a lead anti-inflammatory candidate starting pivotal trials for $400 million. In addition we received potential IBD/Acne/HS candidates ranging from preclinical to mid-stage trials. Additionally, mid-stage p53 modulator was also acquired."
I think Pfizer, Roche, Novartis, or Merck shareholders would be very pleased with such an announcement.